Fisher Wallace Laboratories is a leading medical device startup focused on the treatment of anxiety, depression and insomnia and is raising capital to scale its non-drug treatment solution. Our easy-to-use, FDA-Cleared technology has been prescribed by over 10,000 providers to over 60,000 patients and has been proven safe and effective in multiple published studies. Patients wear our device for 20 minutes in the morning and 20 minutes before bed to treat anxiety, depression and/or insomnia.
Our prescription device is primarily sold through our medical e-commerce website. Prescriptions are often obtained via telemedicine and the device is then FedExed to the patient's door. During the COVID-19 pandemic, demand surged and patients who had no other access to care were able to obtain and use our device to treat symptoms.
Fisher Wallace has enjoyed extensive coverage in leading media outlets including Forbes, The Wall Street Journal, CBS, Fox News, The Atlantic, Scientific American, The Huffington Post, The Daily Beast, The Boston Globe and The Daily Mail.
Fisher Wallace has signed an agreement with StartEngine to participate in StartEngine Secondary, a new investor trading platform that will match orders for buyers and sellers of Fisher Wallace securities. Fisher Wallace will not join this platform until after its closes its current equity crowdfunding campaign. Listing on StartEngine Secondary provides shareholders access to a marketplace for their shares.
UP TO 10X SMALLER AND LIGHTER AND 30% MORE EFFICIENT
We develop advanced rotary engines based on our patented HEHC thermodynamic cycle and engine architecture. LiquidPiston engines are designed to be:
Up to 80% smaller and lighter than the traditional piston Diesel engines.
Only two primary moving parts, optimally balanced.
Up to 30% decrease in fuel consumption, lower CO₂ emission and lower cost of running an engine.
With lower pressure exhaust and just two moving components that are optimally balanced, the engine is inherently quiet, and offers exceptionally low vibration.
Fisher Wallace is working hard to become one of the world’s leading mental healthcare companies - and the #1 brand for the brain. When you purchase $1500 or more equity in Fisher Wallace on StartEngine (an SEC-regulated equity crowdfunding platform) you will receive a free Fisher Wallace device.
Acquired original patents and FDA Clearance (510k) from inventors Saul and Bernard Liss
Completed study of bipolar depression patients conducted at Mount Sinai Beth Israel Hospital
Approved for Over-the-Counter (OTC) sale in Europe and Canada
Over 10,000 devices sold in a single year
FDA announced company’s approval path for depression, anxiety and insomnia
Lowered manufacturing cost by 60%
Started three clinical trials for FDA Approval
Submission of clinical trial data to FDA
Release of Version 2.0 device
Earliest expected date of FDA approval
For the past decade, Kelly Roman has helped lead the fields of neuromodulation product development, regulatory affairs, healthcare marketing and clinical trial strategy. Prior to co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries. He recently served on the boards of two charter high schools in New York City.
Charles “Chip” Fisher grew up in the electronics business before helping pioneer the neuromodulation industry - his father, Avery Fisher, founded Fisher Radio (later named Fisher Electronics). After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s largest shareholder - and recent TEDx contributor.